RWEソリューション市場：コンポーネント別、治療領域別、エンドユーザー別、地域別、2025-2033年

RWEソリューション市場の世界市場規模は2024年に19億米ドルに達しました。今後、IMARC Groupは、2033年には36億米ドルに達し、2025年から2033年にかけて7.3%の成長率（CAGR）を示すと予測しています。

RWEとは、リアルワールドデータ（RWD）を通じて得られる医療製品の使用や潜在的なベネフィットやリスクに関する臨床エビデンスのことです。無作為化試験、大規模単純試験、実用試験、観察研究など、さまざまな研究デザインや分析によって作成することができます。投与量、コンプライアンス、アドヒアランス、適応外使用、有効性と安全性のバランスなど、患者群における現実の治療パターンに関する洞察を提供します。また、RWE ソリューションは、研究者が可能性のある患者を発見し、臨床試験の適切な包含基準を開発するのを支援し、より優れた試験前研究を設計するのに役立つため、世界中でRWEソリューションの需要が高まっています。

RWEソリューション市場動向：

新製品の安全性と有効性に関する正確で明確な情報を得るためのRWEソリューションに対する需要の高まりは、市場を牽引する重要な要因の一つです。さらに、複雑で合併症のある患者が使用する際に、様々な反応、製品の亜集団効果、製品価値を検出するためのソリューションに対する需要が増加しています。これは、急成長するヘルスケア産業とともに、市場の成長を促進しています。さらに、臨床開発、商業化、技術革新のスピードアップ、ヘルスケア成果の改善の加速のためのRWEにおける高度な分析と技術ソリューションの活用の拡大は、市場にプラスの影響を与えています。これに加えて、医薬品やワクチンの有効性を提供するRWEソリューションの使用を促進するために、いくつかの国の政府によって実施されている様々なイニシアチブがあります。これは、量から価値ベースのケアへのシフトと相まって、業界の投資家に有利な成長機会を提供しています。これとは別に、デジタル化と患者中心のバーチャルケアの採用が拡大していることが、RWEソリューションの需要を刺激しています。さらに、がん、肥満、糖尿病などの慢性疾患の有病率は世界中で増加しています。これに伴い、医薬品開発の遅れとそれに伴う開発コストの増加が市場の成長を後押ししています。

本レポートで扱う主な質問

• 2024年の世界のRWEソリューション市場の市場規模は？
• 2025-2033年におけるRWEソリューション市場の世界市場成長率は？
• 世界のRWEソリューション市場を牽引する主要因は何か？
• 世界のRWEソリューション市場に対するCOVID-19の影響は？
• 世界のRWEソリューション市場のコンポーネント別内訳は？
• 世界のRWEソリューション市場の治療領域別の内訳は？
• 世界のRWEソリューション市場のエンドユーザー別の内訳は？
• 世界のRWEソリューション市場における主要地域は？
• 世界のRWEソリューション市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界のRWEソリューション市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：コンポーネント別

• 臨床設定データ
• 請求データ
• 患者主導データ
• 薬局データ
• その他

第7章 市場内訳：治療領域別

• 腫瘍
• 免疫
• 神経
• 心血管疾患
• その他

第8章 市場内訳：エンドユーザー別

• 製薬・医療機器会社
• 医療保険者
• 医療提供者
• その他

第9章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場内訳：国別

第10章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第13章 価格分析

第14章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Aetion Inc.
  • Clinigen Limited
  • Flatiron Health Inc.（Roche Holding AG）
  • ICON plc
  • International Business Machines Corporation
  • IQVIA
  • Optum Inc.（UnitedHealth Group Incorporated）
  • Oracle Corporation
  • Parexel International Corporation
  • PPD Inc.（Thermo Fisher Scientific Inc.）
  • Sas Institute Inc.
  • Syneos Health

List of Figures

• Figure 1: Global: Real-World Evidence Solutions Market: Major Drivers and Challenges
• Figure 2: Global: Real-World Evidence Solutions Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Real-World Evidence Solutions Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 4: Global: Real-World Evidence Solutions Market: Breakup by Component (in %), 2024
• Figure 5: Global: Real-World Evidence Solutions Market: Breakup by Therapeutic Area (in %), 2024
• Figure 6: Global: Real-World Evidence Solutions Market: Breakup by End User (in %), 2024
• Figure 7: Global: Real-World Evidence Solutions Market: Breakup by Region (in %), 2024
• Figure 8: Global: Real-World Evidence Solutions (Clinical Settings Data) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 9: Global: Real-World Evidence Solutions (Clinical Settings Data) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 10: Global: Real-World Evidence Solutions (Claims Data) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: Real-World Evidence Solutions (Claims Data) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: Real-World Evidence Solutions (Patient-Powered Data) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: Real-World Evidence Solutions (Patient-Powered Data) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: Real-World Evidence Solutions (Pharmacy Data) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: Real-World Evidence Solutions (Pharmacy Data) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: Real-World Evidence Solutions (Other Components) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: Real-World Evidence Solutions (Other Components) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: Real-World Evidence Solutions (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: Real-World Evidence Solutions (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: Global: Real-World Evidence Solutions (Immunology) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: Global: Real-World Evidence Solutions (Immunology) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: Global: Real-World Evidence Solutions (Neurology) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: Global: Real-World Evidence Solutions (Neurology) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: Global: Real-World Evidence Solutions (Cardiovascular Disease) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 25: Global: Real-World Evidence Solutions (Cardiovascular Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 26: Global: Real-World Evidence Solutions (Other Therapeutic Areas) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 27: Global: Real-World Evidence Solutions (Other Therapeutic Areas) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 28: Global: Real-World Evidence Solutions (Pharmaceutical and Medical Device Companies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 29: Global: Real-World Evidence Solutions (Pharmaceutical and Medical Device Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 30: Global: Real-World Evidence Solutions (Healthcare Payers) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 31: Global: Real-World Evidence Solutions (Healthcare Payers) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 32: Global: Real-World Evidence Solutions (Healthcare Providers) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 33: Global: Real-World Evidence Solutions (Healthcare Providers) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 34: Global: Real-World Evidence Solutions (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 35: Global: Real-World Evidence Solutions (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 36: North America: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 37: North America: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 38: United States: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 39: United States: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 40: Canada: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 41: Canada: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 42: Asia-Pacific: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 43: Asia-Pacific: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 44: China: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 45: China: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 46: Japan: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 47: Japan: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 48: India: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 49: India: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 50: South Korea: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 51: South Korea: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 52: Australia: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 53: Australia: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 54: Indonesia: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 55: Indonesia: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 56: Others: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 57: Others: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 58: Europe: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 59: Europe: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 60: Germany: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 61: Germany: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 62: France: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 63: France: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 64: United Kingdom: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 65: United Kingdom: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 66: Italy: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 67: Italy: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 68: Spain: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 69: Spain: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 70: Russia: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 71: Russia: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 72: Others: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 73: Others: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 74: Latin America: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 75: Latin America: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 76: Brazil: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 77: Brazil: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 78: Mexico: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 79: Mexico: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 80: Others: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 81: Others: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 82: Middle East and Africa: Real-World Evidence Solutions Market: Sales Value (in Million USD), 2019 & 2024
• Figure 83: Middle East and Africa: Real-World Evidence Solutions Market: Breakup by Country (in %), 2024
• Figure 84: Middle East and Africa: Real-World Evidence Solutions Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 85: Global: Real-World Evidence Solutions Industry: SWOT Analysis
• Figure 86: Global: Real-World Evidence Solutions Industry: Value Chain Analysis
• Figure 87: Global: Real-World Evidence Solutions Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Real-World Evidence Solutions Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Real-World Evidence Solutions Market Forecast: Breakup by Component (in Million USD), 2025-2033
• Table 3: Global: Real-World Evidence Solutions Market Forecast: Breakup by Therapeutic Area (in Million USD), 2025-2033
• Table 4: Global: Real-World Evidence Solutions Market Forecast: Breakup by End User (in Million USD), 2025-2033
• Table 5: Global: Real-World Evidence Solutions Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 6: Global: Real-World Evidence Solutions Market: Competitive Structure
• Table 7: Global: Real-World Evidence Solutions Market: Key Players

The global real-world evidence solutions market size reached USD 1.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.6 Billion by 2033, exhibiting a growth rate (CAGR) of 7.3% during 2025-2033.

Real-world evidence (RWE) refers to clinical evidence about the use and potential benefits or risks of medical products via real-world data (RWD). It can be produced via different study designs or analyses, including randomized trials, big simple trials, pragmatic trials, and observational studies. It provides insight into real-world treatment patterns in patient groups, including dosing, compliance, adherence, off-label use, and the balance between efficacy and safety. As it can also assist researchers in discovering possible patients and developing correct inclusion criteria for clinical trials, which can help them design better pre-trial studies, there is a rise in the demand for RWE solutions around the world.

Real-World Evidence Solutions Market Trends:

The growing demand for RWE solutions to get precise and clear information about the safety and efficacy of new products represents one of the key factors driving the market. Moreover, there is a rise in the demand for these solutions to detect varied reactions, product subpopulation effects, and product value when utilized by complex and comorbid patients. This, along with the burgeoning healthcare industry, is propelling the growth of the market. Additionally, the growing utilization of advanced analytics and technological solutions in RWE for clinical development, commercialization, speed innovation, and accelerating improvements in healthcare outcomes is positively influencing the market. Besides this, there are various initiatives undertaken by governments of several countries to promote the use of RWE solutions, which provide the efficacy of drugs and vaccines. This, coupled with a shift from volume to value-based care, is offering lucrative growth opportunities to industry investors. Apart from this, the growing adoption of digitalization and patient-centered virtual care is catalyzing the demand for RWE solutions. Furthermore, there is an increase in the prevalence of chronic diseases, such as cancer, obesity, and diabetes, across the globe. In line with this, the rising delays in drug development and the subsequent increase in development costs are bolstering the growth of the market.

Key Market Segmentation:

Breakup by Component:

• Clinical Settings Data
• Claims Data
• Patient-Powered Data
• Pharmacy Data
• Others

Breakup by Therapeutic Area:

• Oncology
• Immunology
• Neurology
• Cardiovascular Disease
• Others

Breakup by End User:

• Pharmaceutical and Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Aetion Inc., Clinigen Limited, Flatiron Health Inc. (Roche Holding AG), ICON plc, International Business Machines Corporation, IQVIA, Optum Inc. (UnitedHealth Group Incorporated), Oracle Corporation, Parexel International Corporation, PPD Inc. (Thermo Fisher Scientific Inc.), Sas Institute Inc. and Syneos Health.

Key Questions Answered in This Report

• 1.What was the size of the global real-world evidence solutions market in 2024?
• 2.What is the expected growth rate of the global real-world evidence solutions market during 2025-2033?
• 3.What are the key factors driving the global real-world evidence solutions market?
• 4.What has been the impact of COVID-19 on the global real-world evidence solutions market?
• 5.What is the breakup of the global real-world evidence solutions market based on the component?
• 6.What is the breakup of the global real-world evidence solutions market based on the therapeutic area?
• 7.What is the breakup of the global real-world evidence solutions market based on the end user?
• 8.What are the key regions in the global real-world evidence solutions market?
• 9.Who are the key players/companies in the global real-world evidence solutions market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Real-World Evidence Solutions Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Component

• 6.1 Clinical Settings Data
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Claims Data
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Patient-Powered Data
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Pharmacy Data
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Therapeutic Area

• 7.1 Oncology
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Immunology
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Neurology
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Cardiovascular Disease
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Pharmaceutical and Medical Device Companies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Healthcare Payers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Healthcare Providers
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Aetion Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Clinigen Limited
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
  • 14.3.3 Flatiron Health Inc. (Roche Holding AG)
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 ICON plc
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 International Business Machines Corporation
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
  • 14.3.6 IQVIA
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Optum Inc. (UnitedHealth Group Incorporated)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Oracle Corporation
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Parexel International Corporation
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 PPD Inc. (Thermo Fisher Scientific Inc.)
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Sas Institute Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 SWOT Analysis
  • 14.3.12 Syneos Health
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis